robust nsclc use support set io comb focal pt
mrk bmi data keytruda opdivo posit domin io market mrk
keytruda chemo data sq nsclc impress late-break solidifi posit us
nsclc market bmi opdivo chemo market robust efficaci match
keytruda enhanc nsclc competit foot lli cyramza inhibitor armo
look solid abbv imbruvica/venclexta data support sale pfe lorlatinib/
talazoparib/dacomitinib data solid roche/azn/nvs/mrk-et news flow expect robust
american societi clinic oncolog annual meet held june chicago
merck buy focu keytruda parp combo offer growth outsid
robust presenc see exhibit reflect breadth depth
keytruda pembrolizumab monotherapi combo clinic plan investor focus result first-lin non-
small cell lung cancer nsclc late-break abstract
sq nsclc highlight includ keytruda data small-cel lung cancer sclc keytruda
parp combin data ovarian cancer well data melanoma gastric renal cell state
postview note view keytruda sale growth allianc revenu lynparza azn
 lenvima eisai deal drive oper margin expans ideal posit use balanc
sheet bolster oncolog pipelin model keytruda sale vs street
host investor event local time monday june
keytruda nsclc mrk anticip data result
keytruda monotherapi nsclc squamou non-squam patient express
result submit late-break abstract expect see data
trial ahead plenari session present sunday june local time remind
top-lin posit os data nsclc patient regardless histolog
 april note look forward assess keytruda durabl seen full dataset
especi efficaci benefit lower level express expect investor also look key
differ design patient characterist could explain success bmi
review abstract asco june
trial evalu patient cut-off fail show statist signific benefit opdivo back note
keytruda chemo sq nsclc anoth highli anticip read-out mrk first interim look evalu keytruda
chemo squamou nsclc patient regardless statu remind top-lin posit overal respons rate orr data
ahead acso confirm submit sbla keytruda chemo sq nsclc base data data abstract base
first interim analysi includ orr data confirm second interim analysi conduct prior includ
progress free surviv overal surviv os data unclear analysi data complet time symposium present
june abstract investig present orr data patient keytruda chemo arm chemo-onli arm
median follow-up month efficaci keytruda chemo orr vs chemo-onli intent-to-treat popul keytruda
chemo superior durat respons dor well respons last month vs chemo look forward see
surviv data june surviv data posit expect fda approv keytruda chemo sq nsclc give access
lung cancer patient nsclc patient
keytruda parp ovarian cancer tripl neg breast cancer addit notabl read-out involv efficaci safeti data
studi keytruda tesaro tsro buy peter lawson parp inhibitor zejula niraparib ovarian cancer tripl neg
breast cancer tnbc remind ink deal worth astrazeneca azn rate juli note co-develop co-commerci
azn parp lynparza across multipl tumor type abstract investig present orr safeti data keytruda zejula recurr ovarian cancer
roc oc trial roc cohort efficacy-evalu patient data-lock base platinum-fre interv time evalu patient
platinum-sensit psen pfi month platinum-resist proc month platinum refractori pref pfi day
efficaci orr evalu proc patient patient respond proc orr vs pref pref orr
psen psen orr one respons also observ patient unknown platinum statu evalu patient brca mutat
orr think like mrk/azn look initi keytruda lynparza trial ovarian cancer near-term
abstract investig present orr safeti data keytruda zejula tnbc januari data cut-off tnbc patient
enrol median prior line therapi rang receiv chemo treatment metastat diseas receiv
type prior neo adjuv therapi efficaci patient efficaci evalu orr dcr respons
on-going data cut-off patient remain treatment median brca mutant group month orr higher patient
vs irrespect brca statu data support mrk/azn decis initi keytruda lynparza trial tnbc near-term
data keytruda chemo sclc note keytruda chemo approv sq nsclc base data lung
cancer patient keytruda would access would sclc abstract investig present orr surviv data keytruda
monotherapi sclc sclc cohort trial trial august data cut-off patient efficaci evalu
efficaci orr mpf month month patient mo month month
although orr gener keytruda appear midway opdivo yervoy opdivo monotherapi bmi studi note
mo slightli better y/o mo month mrk sclc result look impress howev small sampl size expect
first-mov advantag sclc assum fda approv opdivo sclc august pdufa date mrk pivot
trial keytruda chemo sclc primari complet januari per clinicaltri gov
keytruda chemo combo data nsclc updat abstract investig present updat surviv data keytruda chemo non-
squamou nsclc cohort trial remind last saw data esmo septemb click
note month follow-up publish confirmatori data click april
month follow-up decemb data cut-off patient evalu median follow-up month efficaci keytruda chemo orr
unchang previou data hr mostli unchang previou median keytruda chemo month vs month
page
chemo keytruda median overal surviv mo still reach year follow-up vs month chemo os hr tick
potenti downward pressur later follow-up two-year os rate keytruda chemo chemo respect
investig conclud risk death keytruda chemo vs chemo reduc nearli half despit high crossov rate among patient
chemo arm improv orr persist note click regulatori file data alreadi review us eu japan
bristol-my buy io chemo similar nktr look promis
robust presenc see exhibit reflect compani deep io pipelin investor focu result part
studi first-lin non-smal cell lung cancer nsclc data bmi io combo posit gain compani
traction model opdivo/yervoy sale vs street bmi investor event schedul local time
monday june chicago
part data competit nsclc bmi anticip data part nsclc studi
compar opdivo yervoy opdivo chemo chemo patient nsclc market share result descript comparison
abstract point hazard ratio measur ci note opdivo chemo hr mostli in-lin
mrk result studi non-squam patient show keytruda chemo hr ci vs chemo patient
categor note alpha alloc analysi descript comparison appear
benefit opdivo chemo robust non-squam vs squamou patient find intrigu chose leav
result abstract separ analysi share safeti result across part studi minimum follow-up
rate grade treatment relat advers event trae vs chemo recal bmi file nsclc high-tmb
nsclc base data note alreadi accept ema assum fda accept immin
opdivo combo data bmy/nektar rate phase trial evalu opdivo continu show robust
respons rate multipl solid tumor recal note compani share impress data rcc nsclc melanoma cohort
abstract bladder/tnbc patient show orr respect part
extend collabor note bmy/nktr pursu opdivo yervoy indic bmi event expect get
updat compani plan initi pivot trial rcc melanoma target
combo idera idra rate alreadi initi trial evalu intratumor yervoy combo
vs yervoy alon patient refractori melanoma receiv fda track design compani present robust interim result
earlier phase studi esmo plan present updat result abstract data show orr patient
slight improv orr patient shown esmo think combo could emerg treatment option
refractori melanoma patient intratumor rout administr put signific disadvantag sinc patient elig
treatment would need access tumor administr
opdivo/ido combo expect low ido inhibitor epacadostat failur combin keytruda melanoma see note keep
eye data bmi ido bladder cancer epacadostat combo opdivo melanoma data earn call
comment ration overal ido program orr ido combin opdivo look robust
bladder cancer io-nav opdivo epacadostat also look impress orr melanoma
rememb epacadostat ido combo keytruda fail show surviv benefit despit robust respons rate melanoma
see rog-ch azn nv mrk-de commentari next page
page
present verzenio sub-analysi
buy cyramza data modest face io focu increas
intrigu oncolog pipelin continu enhanc acquisit click
aurka privat acquisit note armo bioscienc armo rate acquisit note
plan present cyramza data phase studi
hepatocellular carcinoma patient high alpha-fetoprotein afp-high recal
orphan indic patient afp-high previous announc meet primari
os secondari endpoint note studi result highlight abstract show
modestli impress efficaci data patient cyramza treatment achiev median os month
vs month placebo arm median cyramza patient
month vs month placebo arm expect file cyramza
expect opdivo domin indic model cyramza sale
verzenio robust launch far us nbrx share approach six month
pre/perimenopaus set women advanc breast cancer typic
pre/perimenopaus patient aggress diseas often pre-treat
gonadotropin-releas hormon gnrh agonist initi therapi lli sub-analysi
show pre/perimenopaus patient better respons rate unselect
popul vs patient also saw improv hazard ratio vs
separ verzenio combo keytruda doesnt appear provid meaning
improv evidenc initi respons rate combo lower
verzenio monotherapi respons shown studi verzenio sale
street
share preliminari safeti efficaci data prexasertib checkpoint kinas chk-
inhibitor basket phase trial across differ tumor type base differ dose respons
identifi go-forward dose dose expans phase trial
abstract data show prexasertib show anti-cancer activ differ tumor type
squamou cell carcinoma cancer sclc etc recal showcas robust preclin data
prexasertib treatment tnbc note on-going early-stag trial ph-
prexasertib across varieti tumor type
armo releas new data on-going basket trial evalu pegilodecakin
pegyl rang tumor type monotherapi combin variou chemo
regimen opdivo keytruda lli gemzar abstract data show peg-dec combin
keytruda/opdivo result orr heavili pre-treat rcc patient median
follow-up month median peg-dec keytruda month nr peg-
dec opdivo final one-year surviv peg-dec keytruda/opdivo impress
well-toler safeti profil think lli acquisit armo make strategi sens given
buy multipl imbruvica venclexta combo appear gain traction
abbv hematolog oncolog hemonc mean less focu compani
think american societi hematolog meet decemb import
imbruvica broad label leadership chronic lymphocyt leukemia cll market comprehens
clinic develop program establish cornerston asset portfolio aim
present result phase studi evalu imbruvica/opdivo combo treatment rcc
patient abstract share patient three experienc dose-limit toxic
dlt two patient prior therapi show partial tumor respons one becam
complet respons later imbruvica combo astrazeneca imfinzi howev show limit anti-
tumor activ phase studi final abbv phase interim data demonstr
imbruvica/rituxan combo signific efficaci advantag roch rog-ch rate
rituxan alon waldenstrm macroglobulinemia hazard ratio rate
vs also look build-out imbruvica label includ interim result
page
approval/
mantl cell lymphoma shine follicular lymphoma selen imbruvica
sale street
relapsed/refractori cll share interim result first patient phase captiv
studi evalu imbruvica venclexta cll abstract show combo
well-toler dose limit toxic observ model venclexta sale vs
note click view abbv announc seek acceler approv rova-t
third line small cell lung cancer patient express sclc setback
necessarili sign asset valu abbv full result triniti studi expect
abstract meaning updat next catalyst rova-t initi data
phase basket studi neuro-endocrin solid tumor data phase studi rova-
plu bmi opdivo yervoy sclc abbv two rova-t pivot studi meru taho
sclc continu enrol patient data anticip
hold increment data lorlatinib tala dacomitinib ahead regulatori review
note postview note consid oncolog must-win area ibranc
mover advantag market place domin leadership posit
class late immuno-oncolog market robust
overal presenc hand abstract expect draw
 merck kgaa mrk-de rate bavencio de minimi player us io market
pool safeti analysi found rate grade infusion-rel reaction
immune-rel advers event restrict bavencio-tr patient respect
bavencio multipl upcom read-out ovarian renal gastric lung
bladder ovarian bavencio sale street
pfe expect fda action prioriti review next-gen tyrosin kinas inhibitor
lorlatinib august also evalu lorlatinib combin bavencio lung
trial initi safety/efficaci data show promis profil bavencio/lorlatinib
combo alk nsclc patient vs bavencio/xalkori model lorlatinib launch reach
sale vs street
plan submit global regulatori file talazoparib parp base phase embraca data
note gbrca breast cancer aim present embraca efficaci data clinic
relev sub-group abstract give sneak peek analysi show
exampl benefit pronounc patient cns-metastas expect tala
exceed sale vs street
dacomitinib also undergo fda/ema review treatment egfr nsclc base head-to-
head studi vs azn iressa dacomitinib pdufa date sept archer-
result share confer unveil final os data
median os dacomitinib treat egfr nsclc patient vs
iressa model daco launch sale vs street
comparison roch azn novarti merck kgaa asset expect drive newsflow
roch rog-ch rate import read-through abstract
compani roch os data phase trial tecentriq
avastin chemo non-squam nsclc alreadi seen data
decemb note new os data releas show ad tecentriq avastin chemo
result extend os month month base result
think roch like find earli adopt tecentriq alk/egfr avastin high-prescrib
result impress mrk offer hr non-sq
page
nsclc patient might difficult compar result due differ dose regimen
trial design differ compar studi mrk would roch
plan report mid-year list roch also plan releas pfs/safeti
result os studi squamou nsclc set late-break recal
roch top-lin result studi march note endpoint met
os met look forward compar roch result mrk
roch eight on-going phase lung cancer trial five expect read
think roch need posit readout competit long-term
nsclc lastli look forward roch evalu tumor mutat burden predict
biomark present roch investor event schedul
local time monday june chicago
astrazeneca azn rate azn sever present asco could
meaning read-through coverag univers recal imfinzi asset approv
stage nsclc posit azn take share us io market azn pursu imfinzi combo
multipl agent data show herceptin combo imbruvica combo
gener anti-tumor activ azn imfinzi monotherapi imfinzi tremelimumab
combo show appreci efficaci gastric cancer separ trial phase phase
trial respect howev note note alreadi first mover
advantag gastric cancer us japan respect
novarti nv rate nv unveil data much anticip
trial evalu kisqali combin fulvestr treatment hr breast cancer
patient receiv line endocrin therapi recal lli verzenio pfe ibranc
comparison note alreadi indic base result share abstract appear
efficaci kisqali could compar verzenio ibranc look forward detail
patient baselin characterist conduct analysi nv top-lin result
pre-menopaus bc patient novemb sub-analysi conclud patient
chemotherapi treatment even endocrin therapi result less surviv benefit kisqali
novarti reli label extens file plan summer reignit kisqali
growth safeti remain signific concern novarti expect result phase
trial inhibitor spartalizumab combin tafinlar mekinist
treatment metastat braf melanoma novarti early-stag clinic abstract
merck kgaa mrk-de rate apart bavencio merck kgaa attent also
focus bifunct fusion protein target tgf result
phase basket trial advanc solid tumor share abstract
share mangeabl safeti profil gener confirm orr patient
human papillomaviru hpv -associ cancer nsclc cohort orr recommend
phase dose patient view
impress respons data look forward commentari respons durabl
page
exhibit io combo agent sale estim strh vs consensu
exhibit inhibitor sale estim strh vs consensu
page
i-o combo cagrbmyrelatlimab i-o strh total includ consensu estim drug compani cover strhcdk strh total includ consensu estim drug compani cover strh us major pharmaceut
exhibit hematology/oncolog agent sale estim strh vs consensu
exhibit parp inhibitor sale estim strh vs consensu
page
hematolog hematolog strh total includ consensu estim drug compani cover strhparp strh total includ consensu estim drug compani cover strh us major pharmaceut
exhibit present
strh research import present highlight blue color import present highlight grey
page
companydrug nametitleabstract idsessionsess typedatestart timeend timelocationmrkkeytrudaphas studi carboplatin-paclitaxel/nab-paclitaxel chemo withor without pembrolizumab pembro patient pt metastat squamou sq non-smal cell lung cancer combin rais bar withimmunotherapyclin scienc symposiumsunday june amhal pembro versu platinum-bas chemotherapi chemo first-lin therapi advanced/metastat nsclc tumor score porportionn score tp open-label phase cancerclin scienc symposiumsunday june pmhall tsrokeytruda phase studi niraparib pembrolizumab patient pt advanc tripleneg breast cancer recurr ovarian cancer roc result roc combin rais bar withimmunotherapyclin scienc symposiumsunday june amhal incykeytruda epacadostatepacadostat plu pembrolizumab versu pembrolizumab alon patient pt unresect metastat melanoma result phase combin rais bar withimmunotherapyclin scienc symposiumsunday june amhal bergenbiokeytruda ii open-label multi-centr studi bemcentinib first-in-class select inhibitor combin pembrolizumab patient advanc immunotherapypost sessionmonday june amhal amrkkeytrudapembrolizumab pembro vs paclitaxel ptx previous treat advanc gastric gastroesophag junction g/gej cancer phase noncolorect canceror abstract sessionmonday june pmari crown theatermrkkeytrudapembrolizumab monotherapi first-lin therapi advanc clear cell renal cell carcinoma accrcc result cohort nonprost canceror abstract sessionsunday june amari crown theatermrkkeytrudaphas studi pembrolizumab advanc small-cel lung cancer sclc cancer non-smal cell local-regional/smallcell/oth thorac cancersor abstract sessionmonday june amhal llykeytruda overal surviv cohort pemetrexed-carboplatin plu pembrolizumab first-lin therapi advanc nonsquam cancernon-smal cell metastaticpost sessionsunday june amhal amrk sndxkeytruda safeti entinostat ent pembrolizumab pembro patient melanoma progress block cancerspost sessionmonday june pmhall amrk aznlynparza zytigaolaparib combin abirateron patient pt metastat castration-resist prostat cancer mcrpc random phase ii canceror abstract sessionmonday june pmhall tsrokeytruda niraparib pembrolizumab patient pt metastat triple-neg breast cancer tnbc phase cancerclin scienc symposiummonday june pmhall llykeytruda pegilodecakinpegilodecakin nivolumab nivo pembrolizumab pembro inpati pt metastat renal cell carcinoma nonprost cancerpost sessionsaturday june amhal amrk llykeytruda verzenioupd efficaci safeti statu patient hr metastat breast cancer administ abemaciclib plu cancermetastaticpost sessionsaturday june amhal amrkkeytrudaa phase ii studi pembrolizumab egfr-mut tyrosin kinas inhibitor tki nave patient advanc cancernon-smal cell metastaticpost sessionsunday june amhal amrk celgkeytruda revlimid dexamethasonea phase random studi pembrolizumab pembro plu lenalidomid len low-dos dexamethason rd versu rd newli diagnos treatment-na multipl myeloma mm malign plasma cell dyscrasiapost sessionmonday june amhal amrk celgkeytruda pomalyst dexamethasonea phase random studi pembrolizumab pembro plu pomalidomid pom dexamethason relapsed/refractori multipl myeloma rrmm malign plasma cell dyscrasiapost sessionmonday june amhal us major pharmaceut
exhibit present cont
strh research import present highlight blue color import present highlight grey
page
companydrug nametitleabstract idsessionsess typedatestart timeend timelocationmrkkeytrudainvestig express respons pembrolizumab pembro gastric cancer gc cervic cancer cc use combin posit score tumor proport score noncolorect cancerpost sessionsunday june amhal amrkkeytruda phase studi anti-human glucocorticoid-induc tumor necrosi factor receptor gitr monoclon antibodi monotherapi combin pembrolizumab patient advanc solid therapeut translat researchpost sessionmonday june amhal amrkkeytrudasafeti efficaci pembrolizumab pembro plu capecitabin cape metastat tripl neg breast cancer cancermetastaticpost sessionsaturday june amhal amrkkeytrudaa phase ii singl arm studi assess efficaci pembrolizumab pembro plu radiotherapi rt metastat tripl neg breast cancer mtnbc cancermetastaticpost sessionsaturday june amhal amrkkeytrudaphas ii trial pembrolizumab metastat cutaneoussquam cell carcinoma cancerspost sessionmonday june pmhall amrk bergenbiokeytruda random phase ib/ii studi select small molecul axl inhibitor bemcentinib combin either dabrafenib/trametinib pembrolizumab patient metastat cancerspost sessionmonday june pmhall amrkkeytrudarandom phase ii studi pembrolizumab stereotact bodi radiotherapi sbrt versu pembrolizumab alon patient advanc non-smal cell lung cancer pembro-rt cancernon-smal cell metastaticpost sessionsunday june amhal overal surviv patient advanc nsclc treat pembrolizumab result cancernon-smal cell metastaticpost sessionsunday june amhal amrk keytruda safeti entinostat ent pembrolizumab pembro patient non-smal cell lung cancer nsclc previous treat cancernon-smal cell metastaticpost sessionsunday june amhal amrk aznlynparza temadorsafeti efficaci combin olaparib temozolomid small cell lung cancer cancernon-smal cell metastaticpost sessionsunday june amhal amrk llykeytruda erbituxan open-label non-random multi-arm phase ii trial evalu pembrolizumab combin cetuximab patient recurrent/metastat r/m head neck squamou cell carcinoma hnscc result interim safeti neck cancerpost sessionsaturday june pmhall amrkkeytrudapembrolizumab pembro versu investig choic paclitaxel docetaxel vinflunin recurr advanc urotheli cancer uc follow-up phase nonprost cancerpost sessionsaturday june amhal amrkkeytrudaupd efficaci safeti single-arm phase studi investig first-lin pembrolizumab pembro cisplatininelig advanc urotheli cancer nonprost cancerpost sessionsaturday june amhal amrk aznkeytruda calquenceimmun profil random phase ii trial acalabrutinib pembrolizumab pa versu pembrolizumab patient metastat urotheli cancer nonprost cancerpost sessionsaturday june amhal amrk rog-chkeytruda avastinphas ib phase ii studi pembrolizumab bevacizumab treatment metastat renal cell carcinoma rcc nonprost cancerpost sessionsaturday june amhal amrk eisaikeytruda lenvimalenvatinib pembrolizumab patient renal cell carcinoma updat nonprost cancerpost sessionsaturday june amhal pembrolizumab pembro docetaxel-refractori metastat castration-resist prostat cancer prostat canceror abstract sessionmonday june pmhall adxsadxs-psa adxs-psa plu pembrolizumab pembro metastat castration-resist prostat cancer prostat cancerpost sessionsaturday june pmhall amrk pfekeytruda xtandipembrolizumab pembro plu enzalutamid metastat castrat resist prostat cancer mcrpc extend follow prostat cancerpost sessionsaturday june pmhall us major pharmaceut
exhibit present cont
strh research import present highlight blue color import present highlight grey
page
companydrug nametitleabstract idsessionsess typedatestart timeend timelocationmrk aznlynparza trial olaparib parp inhibitor vistusertib recurr endometri ovarian tripl neg breast canceror abstract sessiontuesday june activ safeti pembrolizumab patient advanc recurr ovarian cancer interim result phase cancerclin scienc symposiumsunday june treatment advanc cervic cancer updatedresult phase cancerpost sessionmonday june pmhall amrk eisai keytruda lenvimalenvatinib pembrolizumab patient advanc endometrialcanc updat cancerpost sessionmonday june pmhall amrk eisai keytruda lenvimaa phase trial lenvatinib plu pembrolizumab patient squamou cell carcinoma head neck cancerpost sessionsaturday june pmhall amrk rog-chkeytruda avastinphas ii studi pembrolizumab pembrolizumab plu bevacizumab recurr glioblastoma rgbm nervou system tumorsor abstract sessionfriday june pembrolizumab patient advanc microsatellit instabl high msi-h colorect cancernon-smal cell metastaticpost sessionsunday june amhal amrk sndxkeytruda phase studi entinostat combin pembrolizumab patient microsatellit stabl metastat colorect colorect cancerpost sessionsunday june amhal amrkkeytrudapembrolizumab pembro patient advanc hepatocellularcarcinoma noncolorect cancerpost sessionsunday june amhal amrk mgnxkeytruda margetuximabmargetuximab plu pembrolizumab gastroesophag adenocarcinoma gea post trastuzumab noncolorect cancerpost sessionsunday june amhal amrkkeytrudapembrolizumab patient previous treat metastat adenocarcinoma squamou cell carcinoma esophagu phase noncolorect cancerpost sessionsunday june amhal amrkkeytrudarandom double-blind phase studi evalu neoadjuv platinum-bas chemotherapi periop pembrolizumab placebo resect stage iib iiia nsclc cancer non-smal cell local-regional/smallcell/oth thorac cancerspost sessionsunday june amhal us major pharmaceut
exhibit present
strh research import present highlight blue color import present highlight grey
page
companydrug nametitleabstract idsessionsess typedatestart timeend timelocationbmyopdivonivolumab nivo platinum-doublet chemotherapi chemo vs chemo first-lin treatment tx advanc non-smal cell lung cancer nsclc tumor express result checkmat cancernon-smal cell metastaticor abstract sessionmonday june pmhall yervoynivolumab nivo limumab vs platinum-doublet chemotherapi chemo first-lin treatment tx advanc non-smal cell lung cancer nsclc safeti analysi patient-report outcom checkmat cancernon-smal cell metastaticpost sessionsunday june amhal abmi nktropdivo agonist plu nivolumab patient advanc solid tumor preliminari phase result immunotherapyor abstract sessionsaturday june pmhall iderayervoy phase studi evalu safeti efficaci intratumor inject agonist imo combin ipilimumab ipi inhibitor refractori cancerspost sessionmonday june pmhall abmyopdivo indoleamin inhibitor incombin nivolumab nivo updat safeti across tumor cohort efficaci pt advanc bladder cancer nonprost cancerpost sessionsaturday june amhal abmi incyopdivo epacadostatepacadostat plu nivolumab advanc melanoma updat phase result cancerspost discuss sessionmonday june pmhall abmi abbvopdivo imbruvicapilot trial ibrutinib plu nivolumab patient metastat renal cell cancer mrcc result dose-find nonprost cancerpost sessionsaturday june amhal abmi mrkopdivo pegilodecakin keytrudapegilodecakin nivolumab nivo pembrolizumab pembro inpati pt metastat renal cell carcinoma nonprost cancerpost sessionsaturday june amhal abmi infiopdivo result first-in-human studi tumor macrophage-target agent combin nivolumab advanc solid immunotherapypost discuss sessionmonday june amhal abmi jnceopdivo biolog clinic activ first class ico agonist antibodi /- nivolumab nivo patient pt advanc immunotherapyor abstract sessionsaturday june pmhall cldxopdivo agonist antibodi varlilumab varli nivolumab nivo colorect ovarian ova cancer phase ph clinic trial immunotherapyor abstract sessionsaturday june pmhall ctmxyervoy interim result first-in-human dose-find trial probodi therapeut pb-tx combin ipilimumab ipi patient pt advanc solid immunotherapypost sessionmonday june amhal abmi altoropdivo alt superagonist combin nivolumab metastat non-smal cell lung cancer on-going experi biomark develop non-random open-label phase ib/ii immunotherapyor abstract sessionsaturday june pmhall slsopdivo galinpepimut-sa phase studi concomit galinpepimut- combinationwith nivolumab nivo patient pt ovarian cancer oc second third cancerpost sessionmonday june pmhall us major pharmaceut
exhibit present cont
strh research import present highlight blue color import present highlight grey
page
companydrug nametitleabstract idsessionsess typedatestart timeend timelocationbmi exelopdivo yervoy cabometyxclin efficaci cabozantinib plu nivolumab cabonivo cabonivo plu ipilimumab cabonivoipi patient pt chemotherapy-refractori metastat urotheli carcinoma muc either nave refractori checkpoint inhibitor nonprost cancerpost sessionsaturday june amhal abmi abbvopdivo veliparibveliparib combin nivolumab platinum doublet chemotherapi ct metastatic/advanc immunotherapypost sessionmonday june amhal abmi llyopdivo cyramzapreliminari result phase studi ramucirumab plu nivolumab patient previous treat advanc gastric adenocarcinoma nivoram noncolorect cancerpost sessionsunday june amhal abmi rog-chopdivo yervoy avastina pilot random studi evalu nivolumab nivo nivo bevacizumab bev nivo ipilimumab ipi patient metastat renal cell carcinoma mrcc elig cytoreduct nephrectomi cn metastasectomi ms post-treat biopsi nonprost cancerpost sessionsaturday june amhal abmyopdivoefficaci safeti nivolumab nivo patient pt advanc recurr uterin cervic corpu cancerpost sessionmonday june pmhall abmyopdivonivolumab nivo mainten maint high-risk hr acutemyeloid leukemia aml malign leukemia myelodysplasticsyndrom allotransplantpost discuss sessionmonday june amhal abmyopdivoadjuv therapi nivolumab nivo versu ipilimumab complet resect stage /iv melanoma updat result phase trial checkmat cancersor abstract sessionmonday june amari crown theaterbmyopdivonivolumab nivo neoadjuv therapi patient resect merkel cell carcinoma mcc checkmat cancersor abstract sessionmonday june amari crown theaterbmi mrkyervoy keytrudaphas ii trial pembrolizumab pembro plu mg/kg ipilimumab ipi immedi follow progress ab melanoma cancerspost sessionmonday june pmhall abmyopdivo yervoycombin ipilimumab ipi nivolumab nivo advanc melanoma follow progress inhibitor swog cancerspost sessionmonday june pmhall abmyopdivooptim manag nivolumab nivo ipilimumab advanc renal cell carcinoma omnivor response-bas phase ii nonprost cancerpost sessionsaturday june amhal us major pharmaceut
exhibit present
strh research import present highlight blue color import present highlight grey
page
companydrug nametitleabstract idsessionsess typedatestart timeend random double-blind placebo-control phase studi ramucirumab versu placebo second-lin treatment patient advanc hepatocellular carcinoma elev baselin alpha-fetoprotein afp follow first-lin sorafenib noncolorect canceror abstract sessionmonday june amari cowen theaterllyverzenioabemaciclib pre/perimenopaus women hr breast cancermetastaticpost sessionsunday june amhal llykeytruda verzenioupd efficaci safeti statu patient hr metastat breast cancer administ abemaciclib plu cancermetastaticpost sessionsaturday june amhal prexasertiba phase dose-escal studi prexasertib checkpoint kinas inhibitor combin cisplatin patient advanc clinic pharmacologyand experiment poster sessionmonday june amhal llykeytruda overal surviv cohort pemetrexed-carboplatin plu pembrolizumab first-lin therapi advanc nonsquam cancernon-smal cell metastaticpost sessionsunday june amhal bmykeytruda pegilodecakinpegilodecakin nivolumab nivo pembrolizumab pembro inpati pt metastat renal cell carcinoma nonprost cancerpost sessionsaturday june amhal verzenioa random phase studi abemaciclib versu docetaxel patient stage iv squamou non-smal cell lung cancer sqnsclc previous treat platinum-bas cancer non-smal cell metastaticpost sessionsaturday june amhal lartruvophas studi olaratumab monotherapi combin doxorubicin vincristine/irinotecan high-dos ifosfamid pediatr patient relaps refractori solid tumor part oncologypost sessionsaturday june amhal lartruvophas studi olaratumab plu gemcitabin docetaxel treatment advanc soft tissu sarcoma st announc phase sessionsaturday june amhal abmi llyopdivo cyramzapreliminari result phase studi ramucirumab plu nivolumab patient previous treat advanc gastric adenocarcinoma nivoram noncolorect cancerpost sessionsunday june amhal us major pharmaceut
exhibit present
strh research import present highlight blue color import present highlight grey
exhibit present
strh research import present highlight blue color import present highlight grey
page
companydrug nametitleabstract idsessionsess typedatestart timeend timelocationabbv aznimbruvica imfinzia multicent studi bruton tyrosin kinas btk inhibitor ibrutinib plu durvalumab patient relapsed/refractori r/r solid clinic pharmacologyand experiment poster sessionmonday june amhal aabbvimbruvica venclextaphas captiv result ibrutinib ibr plu venetoclax ven first-lin chronic lymphocyt leukemia malign lymphoma chroniclymphocyt leukemiaor abstract sessionsunday june respons venetoclax ven patient cll relapsed/ refractori ibrutinib and/or malign lymphoma chroniclymphocyt leukemiapost sessionmonday june amhal aabbvrova-tefficaci safeti rovalpituzumab tesirin patient line small cell lung cancer result phase triniti cancer non-smal cell local-regional/smallcell/oth thorac cancersor abstract sessionmonday june amhal abbvopdivo imbruvicapilot trial ibrutinib plu nivolumab patient metastat renal cell cancer mrcc result dose-find nonprost cancerpost sessionsaturday june amhal aabbv rog-chimbruvica rituxanrandom phase trial ibrutinib/rituximab vs placebo/rituximab waldenstrm malign plasma cell dyscrasiaor abstract sessionfriday june respons progress free surviv cll patient malign lymphoma chroniclymphocyt leukemiapost sessionmonday june amhal aabbv amgnvenclexta kyprolisphas studi venetoclax plu carfilzomib dexamethason patient relapsed/refractori multipl malign plasma cell dyscrasiaor abstract sessionfriday june abbvopdivo veliparibveliparib combin nivolumab platinum doublet chemotherapi ct metastatic/advanc immunotherapypost sessionmonday june amhal aabbv nvsimbruvica buparlisibphas i/ii clinic trial ibrutinib buparlisib relapsed/refractori diffus larg b-cell lymphoma mantl cell lymphoma follicular malign lymphoma chroniclymphocyt leukemiapost sessionmonday june amhal acompanydrug nametitleabstract idsessionsess typedatestart timeend timelocationpfetalazoparibembraca efficaci outcom clinic relev subgroup compar talazoparib tala oral poli ribos polymeras parp inhibitor physician choic therapi pct patient advanc breast cancer germlin brca cancermetastaticpost sessionsaturday june amhal apfebavencioassoci efficaci advers event special interest avelumab javelin solid tumor javelin merkel immunotherapypost sessionmonday june amhal apfedacomitinibdacomitinib daco versu gefitinib gef first-lin treatment advanc nsclc archer final overal surviv os cancer non-smal cell metastaticor abstract sessionmonday june pmhall apfebavencio lorlatinib xalkoriavelumab combin crizotinib lorlatinib patient previous treat advanc nsclc phase result javelin lung oncogene-driven non-smal cell lung cancer caution indic clinic scienc symposiumfriday june pmhall us major pharmaceut
exhibit present cont
strh research import present highlight blue color import present highlight grey
page
companydrug nametitleabstract idsessionsess typedatestart timeend ibrancephas ib studi gedatolisib combin palbociclib endocrin therapi et women estrogen receptor er posit metastat breast cancer mbc cancermetastaticpost sessionsaturday june amhal apfebavenciophas studi avelumab advanc previous treat mesothelioma long-term follow-up javelin solid cancer non-smal cell local-regional/smallcell/oth thorac cancerspost sessionsunday june amhal apfelorlatiniblorlatinib patient pt previous treat alk advanc non-smal cell lung cancer nsclc updat efficaci cancer non-smal cell metastaticpost sessionsunday june amhal apfebavencioavelumab patient platinum-tr advanc nsclc follow-up javelin solid tumor cancer non-smal cell metastaticpost sessionsunday june amhal apf llybavencio erbituxavelumab cetuximab combin folfox patient previous untreat metastat colorect cancer mcrc result safeti run-in phase phase ii avetux trial colorect cancerpost sessionsunday june amhal apf bayerxtandi nexavarphas studi enzalutamid without sorafenib sora patient pt advanc hepatocellular carcinoma noncolorect cancerpost sessionsunday june amhal apf jnjxtandi zytigath propheci trial multicent prospect trial circul tumor cell ctc detect men mcrpc receiv abirateron enzalutamid prostat canceror abstract sessionmonday june pmhall jnjxtandi zytiga prednisonephas random cross-ov trial abirateron prednison abi vs enzalutamid patient pt metastat castrat resist prostat cancer mcprc result prostat cancerpost sessionsaturday june pmhall amrk pfekeytruda xtandipembrolizumab pembro plu enzalutamid metastat castrat resist prostat cancer mcrpc extend follow prostat cancerpost sessionsaturday june pmhall apfextandi xofigophas ii safeti toler studi combin enzalutamid patient pt metastat castration-resist prostat cancer mcrpc ctrial-i icorg prostat cancerpost sessionsaturday june pmhall apf jnjxtandi zytiga prednisoneefficaci toler first-lin abirateron prednison abi versu enzalutamid metastat castration-resistantpost cancer mcrpc men year retrospect cohort prostat cancerpost sessionsaturday june pmhall apfextandi xofigosafeti data phase ii random trial dichlorid plu enzalutamid vs alon men metastat castrat refractori prostat cancer prostat cancerpost sessionsaturday june pmhall apf llyibranc erbituxmulticent phase ii trial palbociclib select cyclin depend kinas inhibitor cetuximab platinum-resist hpv unrel recurrent/metastat head neck squamou cell carcinoma rm neck canceror abstract sessionsunday june amhal llybavencio erbituxavelumab-cetuximab-radiotherapi rt versu standard care soc local advanc squamou cell carcinoma head neck scchn safeti phase random trial gortec neck cancerpost sessionsaturday june pmhall apfetalazoparib placebo-control phase studi talazoparib tala background enzalutamid metastat castration-resist prostat cancer mcrpc dna damag repair prostat cancerpost sessionsaturday june pmhall us major pharmaceut
exhibit rog-ch present
strh research import present highlight blue color import present highlight grey
page
companydrug nametitleabstract idsessionsess typedatestart timeend timelocationrog-chtencentriq primari safeti analysi random phase studi atezolizumab carboplatin paclitaxel nabpaclitaxel vs carboplatin nab-paclitaxel therapi advanc squamou cancer non-smal cell metastaticor abstract sessionmonday june pmhall surviv os analysi random ph studi atezolizumab atezo chemotherapi chemo bevacizumab bev vs chemo bev nonsquam nsq cancer non-smal cell metastaticor abstract sessionmonday june pmhall high tissu tmb atezolizumab efficaci across multipl tumor biologyor abstract sessiontuesday june clinic evalu blood-bas tumor mutat burden btmb predict biomark atezolizumab atezo non-smal cell lung cancer nsclc interim biologyor abstract sessiontuesday june rog-chimfinzi herceptina phase studi antibodi durvalumab combin trastuzumab posit metastat breast cancer mbc progress prior anti therapi cctg cancermetastaticpost sessionsaturday june amhal arog-ch keytruda tencentriqpropel phase trial agonist combin pembrolizumab atezolizumab patient pt advanc solid immunotherapypost sessionmonday june amhal arog-chtencentriq avastincolorect cancer metastat dmmr immuno-therapi commit studi nrg- random phase studi combin chemotherapi without atezolizumab atezolizumab monotherapi first-lin treatment patient defici dna mismatch repair dmmr metastat colorect colorect cancerpost sessionsunday june amhal arog-chtencentriq avastinsafeti clinic activ atezolizumab bevacizumab phase ib studi hepatocellular carcinoma noncolorect cancerpost sessionsunday june amhal arog-chtencentriqa phase ii studi investig safeti efficaci neoadjuv atezolizumab muscl invas bladder cancer nonprost cancerpost sessionsunday june amari crown theaterbmi rog-chopdivo avastin yervoya pilot random studi evalu nivolumab nivo nivo bevacizumab bev nivo ipilimumab ipi patient metastat renal cell carcinoma mrcc elig cytoreduct nephrectomi cn metastasectomi ms post-treat biopsi nonprost cancerpost discuss sessionsaturday june amhal arog-chtencentriqatezolizumab atezo first-lin cisplatin-inelig platinumtr local advanc metastat urotheli cancer muc long-term efficaci phase studi nonprost cancerpost sessionsaturday june amhal aazn rog-chcalqu rituxanacalabrutinib alon combin rituximab follicular lymphoma malign lymphoma chroniclymphocyt leukemiapost sessionmonday june amhal us major pharmaceut
exhibit azn present cont
strh research import present highlight blue color import present highlight grey
page
companydrug nametitleabstract idsessionsess typedatestart timeend timelocationazn rog-chimfinzi herceptina phase studi antibodi durvalumab combin trastuzumab posit metastat breast cancer mbc progress prior anti therapi cctg cancermetastaticpost sessionsaturday june amhal aazn abbvimbruvica imfinzia multicent studi bruton tyrosin kinas btk inhibitor ibrutinib plu durvalumab patient relapsed/refractori r/r solid clinic pharmacologyand experiment poster sessionmonday june amhal aaznimfinzi tremelimumabsafeti efficaci durvalumab combin tremelimumab durvalumab monotherapi tremelimumab monotherapi patient advanc gastric noncolorect cancerpost sessionsunday june amhal aaznimfinzisafeti clinic activ durvalumab monotherapi patient gastroesophag noncolorect cancerpost sessionsunday june amhal aazn iph-frimfinzi monalizumafirst-in-human dose escal monalizumab plu durvalumab expans patient metastat microsatellite-st colorect cancerpost sessionsunday june amhal aaznimfinzi oleclumabsafeti efficaci pharmacodynam pd oleclumab alon combin durvalumab advanc colorect cancer pancreat cancer noncolorect cancerpost sessionsunday june amhal aazn acertacalqu combin patient pt relapsed/refractori r/r b-cell nonprost cancerpost sessionsaturday june amhal aaznimfinzi tremelimumabapach open label random phase studi durvalumab durva alon combin tremelimumab treme patient pt advanc germ cell tumor gct result end first nonprost cancerpost sessionsaturday june amhal aazn acertacalqu combin patient pt relapsed/refractori r/r b-cell malign lymphoma chroniclymphocyt leukemiapost sessionmonday june amhal aaznimfinzi tremelimumabsafeti clinic activ durvalumab combin tremelimumab extens diseas small-cel lung cancer cancer non-smal cell local-regional/smallcell/oth thorac cancerspost sessionsunday june amhal us major pharmaceut
exhibit nv present
strh research import present highlight blue color import present highlight grey
page
companydrug nametitleabstract idsessionsess typedatestart timeend timelocationnvskisqaliribociclib rib fulvestr postmenopaus women hormon receptor-posit hr advanc breast cancer result cancermetastaticor abstract sessionsunday june amhal soltamoxribociclib rib tamoxifen tam non-steroid aromatas inhibitor nsai premenopaus women hormon receptorposit hr advanc breast cancer receiv prior chemotherapi ct subgroup cancermetastaticpost sessionsaturday june amhal i/ii studi spartalizumab patient pt advanc immunotherapypost sessionmonday june amhal ib/ii studi lacnotuzumab combin spartalizumab patient pt advanc immunotherapypost discuss sessionmonday june amhal i/ii studi spartalizumab mab patient anaplast thyroid neck cancerpost sessionsaturday june pmhall anvskisqaliribecca phase iiib multi-cent open label studi women estrogen receptor posit local advanc metastat breast cancer treat ribociclib combin letrozol result first interim cancermetastaticpost sessionsaturday june amhal anvskisqaliribociclib ribo letrozol let patient pt hormonereceptor-posit hr human epiderm growth factor receptor advanc breast cancer prior endocrin therapi et preliminari result phase cancermetastaticpost sessionsaturday june amhal abmi nvsopdivo tafinlar mekinistsafeti preliminari activ data singl center phase iistudi triplet combin nivolumab dabrafenib trametinib trident patient pt braf-mut metastat melanoma cancerspost sessionmonday june pmhall phase open-label studi combin spartalizumab patient advanc solid tumor hematolog clinic pharmacologyand experiment poster sessionmonday june amhal us major pharmaceut
exhibit mrk-de present
strh research import present highlight blue color import present highlight grey
page
companydrug nametitleabstract idsessionsess typedatestart timeend activ bifunct fusion protein target tgf- patient hpv associ therapeuticsimmunotherapyor abstract sessionsaturday june pmhall second-lin nsclc cohort treat bifunct fusion protein target tgf- cancernon-smal cell metastaticpost discuss sessionsunday june amhal recommend phase dose bifunct fusion protein target tgf- therapeuticsclin pharmacolog experiment therapeuticspost sessionmonday june pmhall us major pharmaceut
valuat risk
price target assum trade ep premium major biopharmaceut peer group expect
abbv trade premium group settl us patent disput humira pipelin matur multipl data read out
immunolog hematolog oncolog asset play model assum humira total sale account sale
immunolog hematology/oncolog sale new product label expans exist asset rise sale
risk rate price target includ earlier expect humira biosimilar competit us market addit assum
compani abl gener revenu pipelin lower humira total revenu
clinic regulatori commerci setback key pipelin asset upadacitinib risankizumab imbruvica venclexta rova-t elagolix etc
could forc look extern acceler diversif sale prior humira loss exclus us invest risk relat
pharmaceut industri gener includ continu price risk payer especi europ polit risk product develop
risk regulatori risk commerci risk legal risk patent challeng
valuat risk
price assum trade ep premium major biopharmaceut peer group believ
deserv premium base growth prospect substanti premium acquisit bid could command pt support
discount cash flow analysi dcf valu believ bmi attract growth dividend yield specul put floor
bmi stock
risk thesi pt includ clinic regulatori commerci competit risk bmi product failur show overal surviv
os benefit trial nsclc could creat set-back io io opdivo yervoy strategi nsclc wherebi
smaller indic might abl make lost opportun yervoy use could primarili limit melanoma renal cell
carcinoma fail physician concern yervoy toxic profil increas also consid portfolio concentr
out-year invest risk io eliqui account project total revenu nevertheless specul
put floor stock valuat view
valuat risk
pt assum trade ep reflect premium current forward group averag
 forward price-to-earnings multipl think premium group averag multipl justifi given lli diversifi volume-driven sale growth
mid-singl digit sale compound-annual-growth-rate oper leverag oper margin goe price target
support discount cash flow dcf intrins valu per share
risk thesi revolv around price commerci execut regulatori clinic risk face upcom patent expir
ciali alimta well recent expir patent strattera competit pressur trulic semaglutid
 humalog biosimilar insulin lispro expect off-set four launch verzenio galcanezumab olumi
baricitinib lasmiditan
valuat risk
page
target price assum merck trade ep estim support discount cash flow dcf model
multipl ep group averag think appropri given mrk leadership immuno-
oncolog space keytruda first-mov advantag nsclc
risk rate target price includ failur capit truda first-mov advantag nsclc approv use
januvia franchis see materi declin sale due rise competit oral dpp-iv segment clinic
regulatori risk keytruda line extensions/new use multipl early-stag io asset cancer alzheim diseas relebactam
infect herp zoster valent pneumococc vaccin global price risk invest risk relat
biopharmaceut industri includ global price risk payer polit risk clinic develop risk regulatori risk commerci
risk legal risk patent challeng
valuat risk
arriv target price assum stock trade ep believ in-lin multipl compar peer
group averag warrant due pfe anem growth outlook higher concentr sale gener eh account
sale view stock range-bound sinc manag demonstr lack urgenc wait macro factor
us tax reform and/or repatri ii binari event io clinic trial could materi alter valuat potenti target
time pfe dividend yield aggress share repurchas add floor stock view dcf analysi yield
intrins valu per share
risk thesi includ increas competit key growth product ibranc xalkori inlyta sutent xtandi xeljanz
bavencio price pressures/high discount rebat demand payer govern greater expect gener price
compress legaci eh product peri-lo addit risk overpay larg biopharma acquisit
convers also note sourc posit risk could includ earlier expect transform drive sharehold return
better expect perform growth asset instanc eliqui posit blood thin market could add signific
upsid pfe allianc revenu xtandi could receiv boost sale perform non-metastat segment prostat
compani mention note
compani buy john bori
astrazeneca azn rate
page
advaxi adx rate
armo bioscienc armo rate
bayer bayn-d rate
celldex rate
cytomx rate
eisai rate
idera idra rate
infin pharmaceut infi rate
innat pharma iph-fr rate
johnson johnson rate
jounc rate
merck kgaa mrk-de rate
nektar rate
roch rog-ch rate
sella sl rate
syndax rate
page
john bori herebi certifi view express research report accur reflect person view subject
compani secur also certifi receiv direct indirect compens
exchang express specif recommend report
